Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma
dc.contributor.author | Sezgin, Canfeza | |
dc.contributor.author | Veral, Ali | |
dc.contributor.author | Karabulut, Bülent | |
dc.contributor.author | Göker, Erdem | |
dc.contributor.buuauthor | Kurt, Ender | |
dc.contributor.buuauthor | Evrensel, Türkkan | |
dc.contributor.buuauthor | Yalçınkaya, Ülviye | |
dc.contributor.buuauthor | Kanat, Özkan | |
dc.contributor.buuauthor | Demiray, Mutlu | |
dc.contributor.buuauthor | Arslan, Murat | |
dc.contributor.buuauthor | Ercan, İlker | |
dc.contributor.buuauthor | Manavoǧlu, Osman | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-2382-290X | tr_TR |
dc.contributor.orcid | 0000-0003-2501-3097 | tr_TR |
dc.contributor.orcid | 0000-0002-9732-5340 | tr_TR |
dc.contributor.researcherid | M-8060-2019 | tr_TR |
dc.contributor.researcherid | AAJ-1027-2021 | tr_TR |
dc.contributor.scopusid | 7006207332 | tr_TR |
dc.contributor.scopusid | 6603942124 | tr_TR |
dc.contributor.scopusid | 6508300295 | tr_TR |
dc.contributor.scopusid | 55881548500 | tr_TR |
dc.contributor.scopusid | 6603631569 | tr_TR |
dc.contributor.scopusid | 57197925370 | tr_TR |
dc.contributor.scopusid | 6603789069 | tr_TR |
dc.contributor.scopusid | 6602587152 | tr_TR |
dc.date.accessioned | 2022-03-11T07:15:16Z | |
dc.date.available | 2022-03-11T07:15:16Z | |
dc.date.issued | 2005-05 | |
dc.description.abstract | In this study, we aimed to investigate the clinicopathological characteristics with special emphasis on c-kit expression and the treatment results of patients with extrapulmonary small cell carcinoma (EPSCC). The medical records of the patients with EPSCC were reviewed, and the data regarding patient and tumour characteristics, treatment and clinical outcome were retrieved and analysed. A total of 28 patients with the diagnosis of EPSCC were identified. There were 19 males and 9 females, with a mean age of 56.5 years. Patients with limited disease (LD) (n = 13) were treated with surgery, chemotherapy (CT) and radiotherapy with different sequences. Patients with extensive disease (ED) (n = 15) were mainly treated with combination CT. The median overall survival was 14.5 months in patients with LD compared to 11 months in those with ED (p = 0.029). Ten patients (36%) showed c-kit overexpression. There was no significant difference between the survival of c-kit-positive and c-kit-negative patients (p = 0.367). In conclusion, our study demonstrates that the prognosis of EPSCC is poor despite currently available treatments. C-kit may be considered as a potential target for novel therapeutical approaches. | en_US |
dc.identifier.citation | Kurt, E. vd. (2005). "Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma". International Journal of Clinical Practice, 59(5), 537-543. | en_US |
dc.identifier.endpage | 543 | tr_TR |
dc.identifier.issn | 1368-5031 | |
dc.identifier.issue | 5 | tr_TR |
dc.identifier.pubmed | 15857349 | tr_TR |
dc.identifier.scopus | 2-s2.0-27144466420 | tr_TR |
dc.identifier.startpage | 537 | tr_TR |
dc.identifier.uri | https://doi.org/10.1111/j.1368-5031.2005.00447.x | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1111/j.1368-5031.2005.00447.x | |
dc.identifier.uri | https://pubmed.ncbi.nlm.nih.gov/15857349/ | |
dc.identifier.uri | http://hdl.handle.net/11452/24943 | |
dc.identifier.volume | 59 | tr_TR |
dc.identifier.wos | 000228307200008 | tr_TR |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.journal | International Journal of Clinical Practice | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | General & internal medicine | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.subject | Extrapulmonary | en_US |
dc.subject | Small cell carcinoma | en_US |
dc.subject | Therapy | en_US |
dc.subject | C-kit | en_US |
dc.subject | Single-institution experience | en_US |
dc.subject | Lung-cancer | en_US |
dc.subject | Protein expression | en_US |
dc.subject | Phase-II | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Bladder | en_US |
dc.subject | Overexpression | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Diagnosis | en_US |
dc.subject | Imatinib | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Carboplatin | en_US |
dc.subject.emtree | Cisplatin | en_US |
dc.subject.emtree | Cyclophosphamide | en_US |
dc.subject.emtree | Doxorubicin | en_US |
dc.subject.emtree | Epirubicin | en_US |
dc.subject.emtree | Etoposide | en_US |
dc.subject.emtree | Fluorouracil | en_US |
dc.subject.emtree | Ifosfamide | en_US |
dc.subject.emtree | Paclitaxel | en_US |
dc.subject.emtree | Stem cell factor receptor | en_US |
dc.subject.emtree | Topotecan | en_US |
dc.subject.emtree | Vincristine | en_US |
dc.subject.emtree | Stem cell factor receptor | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer survival | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Clinical feature | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Demography | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Histopathology | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Immunohistochemistry | en_US |
dc.subject.emtree | Kaplan meier method | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Medical record | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Prognosis | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Small cell carcinoma | en_US |
dc.subject.emtree | Treatment outcome | en_US |
dc.subject.emtree | Adjuvant chemotherapy | en_US |
dc.subject.emtree | Adjuvant therapy | en_US |
dc.subject.emtree | Disease free survival | en_US |
dc.subject.emtree | Gastrointestinal tumor | en_US |
dc.subject.emtree | Gene expression | en_US |
dc.subject.emtree | Genetics | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Small cell carcinoma | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Carcinoma, small cell | en_US |
dc.subject.mesh | Chemotherapy, adjuvant | en_US |
dc.subject.mesh | Disease-free survival | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gastrointestinal neoplasms | en_US |
dc.subject.mesh | Gene expression | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Proto-oncogene proteins c-kit | en_US |
dc.subject.mesh | Radiotherapy, adjuvant | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Treatment outcome | en_US |
dc.subject.scopus | Small Cell Carcinoma; Neuroendocrine Carcinoma; Esophagus | en_US |
dc.subject.wos | Medicine, general & internal | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.title | Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma | en_US |
dc.type | Article | |
dc.wos.quartile | Q2 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: